Chanie joined Novo Ventures (US) Inc. as an associate in the Boston location in August 2022. Chanie previously worked in corporate strategy and business development at Evozyne Biosciences, an early stage AI/ML generative biology company. Prior to Evozyne, she was a Senior Associate on Evercore ISI’s Biotech Team where she focused on coverage of SMID-cap biotechnology companies.
Chanie holds a PhD in Immunology from the University of Chicago, where she studied the role of the immune system in respiratory disease. She also holds a BSc/MSc dual degree with a concentration in Immunology from Emory University.